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Background and aims: ABO encodes a glycosyltranferase which determines the major human
histo-blood group. The FUT2 fucosyltransferase allows expression of ABO antigens on the
gastrointestinal mucosa and in bodily secretions (secretor phenotype). A nonsense allele in FUT2
represents a susceptibility variant for Crohn's disease, and both the secretor and ABO blood
group status affect the composition of the gut microbiota. Thus, we evaluated if variants in ABO
might represent good candidates as Crohn's disease susceptibility loci.
Methods: We recruited two case–control cohorts, from Italy (n = 1301) and Belgium (n = 2331).
Subjects were genotyped for one SNP in FUT2 and two variants in ABO.
Results: No effect on Crohn's disease risk was detected for ABO variants, whereas an association
was observed between the FUT2 polymorphism and Crohn's disease susceptibility in the Belgian
sample, but not in the Italian cohort. The effect of histo-blood groups was evaluated using group
O as the reference. Most non-O groups had odds ratios (ORs) higher than 1 in both cohorts, and
combined analysis of the two samples indicated a predisposing effect for the A and B groups
(OR = 1.17, 95% CI: 1.02–1.32 and OR = 1.33, 95% CI: 1.09–1.58, respectively). In Crohn'satics, Scientific Institute IRCCS E. MEDEA, 23842 Bosisio Parini, Italy. Tel.: +39 031877915; fax: +39
.lnf.it (M. Sironi).
to this work.
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490 D. Forni et al.disease patients, the non-O blood group and the non-secretor status were associated with higher
risk of developing a stricturing or penetrating disease.
Conclusions: ABO histo-blood group might confer susceptibility to Crohn's disease and modulate
disease severity.







The ABO gene encodes a polymorphic glycosyltranferase
which transfers N-acetyl D-galactosamine (group A) or D-ga-
lactose (group B) to a common substrate (antigen H). ABO
loss of function variants result in the O blood group. In
humans an α (1,2)-fucosyltransferase encoded by FUT2 (Se
enzyme, Lewis blood group system) determines the expres-
sion of the H antigen in secretory glands and on the surface
of epithelial cells. Individuals referred to as “secretors”
have at least one functional FUT2 allele and display H and
ABO histo-blood group antigens on the gastrointestinal
mucosa. Common FUT2 null variants are present in many
populations; in particular a frequent stop codon allele
(se428) is responsible for most non-secretor phenotypes in
Europe.1
The secretor/non-secretor trait has been associated
with several conditions such as development of duodenal
ulcerations and predisposition to oral candidiasis, as well as
susceptibility to different infections, including those caused
by cholera, Norovirus, and Helicobacter pylori (reviewed in
Ref. 2). These same pathogens have been shown to affect the
host with variable severity depending on the ABO blood group
status.2 In fact, both pathogenic and commensal microorgan-
isms exploit oligosaccharides on the gastrointestinal mucosa
for adherence. For example some lactobacilli specifically bind
A antigens3 whereas Lactobacillus plantarum recognizes both
A and B-oligosaccharides.4 Thus, secretor and ABO blood group
status affects both the predisposition to specific infections
and the composition of the gut microbiota. For example
bifidobacterial diversity and abundance are reduced in the
intestine of non-secretor individuals,5 whereas subjects
carrying the B antigen show higher diversity of Clostridium
species.6
Host–microbe interactions in the gut mucosa are thought
to play a role in several human conditions, including Crohn's
disease (CD), a chronic inflammatory disease of the gastroin-
testinal tract.7 CD results from a combination of genetic
and environmental risk factors, and recent evidence has
indicated that the common non-secretor allele represents
a risk factor for the diseases8,9 in populations of European
ancestry. Subsequent analyses indicated that the FUT2
genotype explains a substantial portion of variability in
microbiota composition between CD patients and healthy
subjects.10 Given the functional interaction between the FUT2
and ABO gene products, as well as the role of both secretor
status and blood group antigens in regulating the gut
microbiota composition, variants in ABO represent potential
candidates as genetic risk factors for CD. Thus, we assessed
the role of ABO single nucleotide polymorphisms (SNPs) and
histo-blood group in predisposing to CD and in affecting
disease presentation.2. Materials and methods
2.1. Subjects
Italian CD patients (333 males, 287 females) and controls
(415 males, 266 females) were recruited by the IBD Unit of
the Luigi Sacco Hospital in Milano, a third-level center for
the management of inflammatory bowel disease (IBD)
patients. The diagnosis of CD was based on international
published criteria, according to clinical, endoscopic, histo-
logical and/or radiological data.11 Controls were subjects
who did not suffer from any pathology at the moment
of recruitment. All patients and controls were unrelated
Italians of European origin. Belgian CD patients (633 males,
889 females) and controls (382 males, 427 females) were
recruited in the framework of the IBD genetics study that
started in 1997 at the IBD unit of the University Hospital in
Leuven, Belgium. Diagnosis of CD was based on standard
clinical, endoscopic and histological criteria. Disease loca-
tion and behavior were recorded according to the Montreal
classification.12 Taking into account that CD behavior and
location vary over the course of the disease in a great
proportion of patients,13 only patients with a minimum of
10 years of follow-up since CD diagnosis were used for the
analysis of disease behavior and location. The controls were
all unrelated, and without a family history of IBD or other
immune related disorders.
The ethical board of the UZ Leuven approved the study
(approval number of Ethical Committee: B322201213950/
S53684). All included participants gave informed consent.
Samples and data were stored in a coded, anonymized
database. DNA was extracted from whole venous blood and
stored at −80 °C.2.2. Genotyping and statistical analyses
Genotyping of rs492602 (FUT2), rs8176749 (ABO) and rs687289
(ABO) was performed by TaqMan probe assays (TaqMan SNP
genotyping assay, Applied Biosystems, Foster City, CA, USA)
using the allelic discrimination real-time PCRmethod.Genotyp-
ing rate was N0.97 for all SNPs.
Association analysis for single variants was performed
using an additive model within a logistic regression frame-
work using the PLINK software.14 Meta-analysis was per-
formed using a random effect model, as implemented in
PLINK.14 The association test between ABO histo-blood group
and CD susceptibility was performed using Fisher's exact test
with the O blood group as a reference. Therefore, odds
ratios (ORs) and confidence intervals (CIs) are presented for
each of the non-O groups and for all non-O groups together.
As above, the combined odds ratios, confidence intervals
491ABO histo-blood group in Crohn's diseaseand p-values were obtained from a random-effect meta-
analysis implemented in the “rmeta” R package.15
Multinomial logistic regression was performed using SPSS.
Logistic regression models with covariates (as specified in
the text) were implemented in R (http://cran.r-project.
org/). Power analysis was performed using the Genetic







To address the possible role of genetic variation in ABO in
conferring susceptibility to CD, we recruited two case–control
cohorts, from mainland Italy and from Belgium. All subjects
were of European ancestry, and they were genotyped for one
SNP in FUT2 and two variants in ABO. In European populations
rs492602 in FUT2 is in full linkage disequilibrium (r2 = 1 in
HapMap CEU and TSI) with the stop codon polymorphism
(rs601338, se428) determining the common non-secretor status.
The two ABO SNPs (rs8176749 and rs687289) were selected to
allow inference of the three major haplotypes (O, A, and B)
which in turn determine blood groups (A, AB, B and O).17
Power estimates indicated that, if each analyzed poly-
morphism/haplotype were to directly confer at least a
1.4-fold increase in the relative risk of CD, the case/control
cohorts used in this study would be of sufficient size to have
a power higher than 80% to detect a significant association at
the 0.05 level assuming a recessive mode of inheritance
both for the FUT2 non-secretor allele and for the O group
haplotype, and a dominant model for the non-O group
haplotypes (considered together).
The two variants in ABO complied with Hardy–Weinberg
equilibrium (HWE) in cases and controls in both the Italian
and Belgian sample (Bonferroni-corrected p-values N0.5).
Conversely, rs492602 in FUT2 significantly deviated from
HWE in Belgian CD patients (corrected p-value = 0.014), but
not in controls or in Italian cases.
Logistic regression was used to compare allele and
genotype frequencies in CD patients and healthy controls
(HC) from both cohorts: no significant effect was detected
for ABO variants in either cohort (Table 1). The FUT2
polymorphism was significantly associated with CD suscep-
tibility in the Belgian sample (Table 1). The G allele of
rs492602 is in phase with the recessive non-secretor stop
codon allele; thus, in line with previous reports,8,9 the
frequency of non-secretor individuals was higher among
Belgian CD subjects (23.9%) compared to Belgian HC (18.3%);
no such difference was evident in the Italian cohortTable 1 Association study for ABO and FUT2 variants with CD in
SNP (gene) Minor allele Italian cohort
Genotype counts p a
CD (n = 620) HC (n = 681)
rs8176749 (ABO) T 9/105/500 1/110/546 0.08
rs687289 (ABO) A 76/301/237 108/279/267 0.80
rs492602 (FUT2) G 137/321/158 142/342/174 0.88
a p-Values calculated using logistic regression using an additive mode
b Random-effect meta-analysis p-value.
c Bonferroni-corrected p-value.(non-secretor frequency = 22.2% and 21.6% in CD patients
and HC, respectively).
We next sought to verify whether any association could
be detected between histo-blood groups and risk of CD.
Thus, ABO haplotypes at rs8176749 and rs687289 were used
to infer each individual's blood group (A and B groups
co-dominant, O group recessive). A minority of subjects (less
than 0.6% in both the Belgian and Italian cohorts) displayed
rare haplotypes and were removed from the analyses as their
blood group could not be inferred. Thus, after accounting for
few failed genotypes in ABO or FUT2 variants, blood group
and secretor status could be determined for 1190 Italian
(572 CD patients, 618 HC) and 2316 Belgian (1512 CD
patients, 804 HC) subjects (Supp. Table 1). In both samples
the A and O groups had similar frequency (slightly higher
than 40%) and the latter was used as a reference for odds
ratio (OR) calculation.
As shown in Fig. 1, the A and B groups had ORs N1 in both
the Italian and the Belgian cohort; a combined analysis
revealed a significant effect of these two groups on CD
susceptibility. The AB status gave contrasting results in the
two samples, possibly due to its low representation in the
population. Overall, the combined analysis indicated that
carrying a non-O blood group might increase the risk of
developing CD (Fig. 1). Similar results were obtained when
only secretor subjects were analyzed (Fig. 1), although the
smaller sample size resulted in significant association in the
combined samples for non-O subjects only. Non-secretors
were not separately analyzed due to their small sample size.
We next assessed whether ABO histo-blood group affects
disease presentation in CD patients. Because disease
location and especially disease behavior tend to vary over
time,13 we included only patients with a follow-up of at least
10 years (i.e. 647 subjects from the Belgian sample).
According to the Montreal classification,12 disease location
was defined as colonic, ileocolonic or ileal; a multinomial
logistic regression that accounted for secretor status and age
at diagnosis revealed no effect of histo-blood group (O vs
non-O) on disease location; no effect was detected for
secretor/non-secretor status, either.
Conversely, disease behavior was found to be affected by
ABO status. Specifically, a logistic regression that accounted for
secretor status, disease location and age at diagnosis revealed
that O subjects are less likely to develop a stricturing (B2) or
penetrating (B3) form than a non-complicated (B1) disease
(OR = 0.70, 95% CI: 0.44–0.98, p = 0.038) (Fig. 2). Likewise,
after accounting for O/non-O histo-blood group (as well as age
at diagnosis and disease location), non-secretors were found totwo case–control cohorts.
Belgian cohort Combined
Genotype counts p a p b(corrected p c)
CD (n = 1522) HC (n = 809)
68 11/211/1296 1/102/706 0.1371 0.0421 (0.1263)
42 179/721/620 102/341/366 0.2050 0.6111 (1)
65 364/702/453 148/375/283 0.0006 0.1500 (0.4500)
l.
Figure 1 Odds ratios and 95% confidence intervals for the A, B, AB, and non-O blood groups relative to blood group O. Analyses were
performed for the Italian (black) and Belgian (dark gray) cohorts and for the combined sample (light gray). Significant p-values are
reported. Analysis for secretor subjects is also shown.






 be at slightly higher risk of stricturing/penetrating behavior
(OR: 1.51, 95% CI: 1.01–2.25, p = 0.046) (Fig. 2).
4. Discussion
In recent years, genome-wide association studies and meta-
analyses have identified 140 susceptibility loci for CD.18Figure 2 Distribution of disease behavior in 647 CD patients
grouped according to O/non-O histo-blood group and secretor
status.
y guest on A
pril 18, 2016Nonetheless, a major portion of genetic risk factors remains
to be identified, as known variants explain less than 25% of
disease heritability.8,19 Some missing risk loci are likely to be
accounted for by common variants with weak effect and by
undetected interactions among genetic factors or between
genes and environmental clues. Thus, analysis of genes that
impinge on common biochemical pathways and have a
potential role in CD pathogenesis might uncover novel
associations. CD is thought to result from an abnormal
immune response to commensal bacterial species, and the
composition of the gut microbiota has been shown to differ
between CD patients and healthy controls.20–23 The identi-
fication of FUT2 as a susceptibility locus for CD,8,9 and the
demonstration that the secretor/nonsecretor status affects
the composition of the gut microbiota5 have supported the
hypothesis that the disease is caused by a combination/
interaction of genetic and environmental effects. Indeed, it
has recently been shown that CD disease status interacts
with the FUT2 genotype in shaping the composition of the
gut microbiota.10 The gene product of FUT2 determines the
expression of the precursor of ABO antigens on the intestinal
mucosa and blood group status has also been shown to affect
the composition of commensal microbial communities.6
These observations make the common ABO variants and the
resulting histo-blood groups very good candidates as modu-
lators of CD susceptibility.
We analyzed variants in ABO and FUT2 in two populations
of European ancestry. The lack of association of single ABO
polymorphisms is consistent with histo-blood group being
specified by haplotypes that display both dominant/reces-
sive and co-dominant behavior. Thus, when blood group
status was analyzed we observed a tendency for non-O
groups to predispose to CD in both cohorts, and a significant
effect of A, B and non-O status in the combined sample was
detected. Stratification on the basis of FUT2 genotypes
493ABO histo-blood group in Crohn's disease






 yielded similar results in secretor subjects. In the Italian
sample we found a similar frequency of non-secretor
individuals in CD patients and healthy controls. A possible
explanation for this finding is that the FUT2 genotype
interacts with environmental factors (e.g. specific commen-
sal/pathogenic species) that differ across geographic loca-
tions; indeed, analysis of gut microbial communities has
unveiled considerable differences among individuals living in
different countries.24
By analyzing a limited number of subjects Miyoshi and
coworkers have suggested that secretors and non-secretors
might be differently prevalent among CD patients depending on
the major site of inflammation (ileal, colonic or ileocolonic).25
In their study the authors also reported that in CD patients and
in Il10−/− mice, an experimental model of CD, the expression
of the ABO and H-antigens is increased in the gut mucosa.
Analysis of Il10−/− mice indicated that H-antigen mucosal
over-expression precedes the onset of inflammatory symp-
toms, suggesting a role in promoting disease pathogenesis.25
Data herein do not support a role for either ABO histo-blood
group or secretor status in affecting disease location; con-
versely, in line with the report by Miyoshi and co-workers, our
results indicate that non-O carriers are at higher risk of
developing a severer disease compared to O-group subjects;
the same observation holds for non-secretors, although
the effect seems to be weaker. These data strengthen the
potential role of non-O blood group status as a CD risk factor
and suggest that genetic modulators of disease susceptibility
also affect CD behavior, as previously shown for other CD risk
variants.26
Nonetheless, given the relationship between the secretor
phenotype and the ABO status, the observations whereby
non-secretors and non-O carriers are at higher CD risk and
present unfavorable disease behavior seem difficult to
reconciliate. Thus, the precise role of H and ABO antigen
expression in CD susceptibility remains to be clarified. In a
recent work species belonging to the Lactobacillus genus were
found to be particularly associated with healthy secretor
subjects compared to CD patients and non-secretors.10 The
authors suggested that this finding is consistent with the
probiotic effect of these bacteria and might derive from their
expression of adhesins for blood group A and B antigens.10,27
Again, this observation suggests a role for ABO group status in
CD susceptibility, but a protective rather than predisposing
role of A and B groupswould be expected. Further analyses are
clearly required to clarify these points. The complex interplay
between genetic and environmental factors influencing
microbial composition, as well as the role of chronic infection
in CD susceptibility, is only beginning to be appreciated. Blood
group antigens are exploited by several pathogenic and
commensal bacterial and viral species for mucosal attach-
ment. Indeed, it has been shown that polymorphisms in the
FUT2 and ABO genes are maintained in human populations by
natural selection.28–31 Thus, subjects with different blood
group and secretor status are susceptible to some infections
and resistant to others.2 Recent evidence has indicated that
chronic infectionswith bacterial species such asMycobacterium
avium32 and Clostridium difficile33 might underlay the patho-
genesis of at least a portion of CD patients. Whether the
susceptibility to these and other pathogens is modulated by the
ABO and secretor/nonsecretor status remains to be evaluated,
but might help explain the associations we report herein and,possibly, that previously described in FUT2. In summary, data
herein suggest a role for non-O histo-blood groups in the
susceptibility to CD and indicate that non-O group carriers and
non-secretors are at high risk of developing a stricturing or
penetrating disease.
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